Medigen Biotechnology (ROCO:3176) Total Tax Payable: NT$8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
58 GF Score
Price NT$39.80
GF Value NT$32.73
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Medigen Biotechnology Total Tax Payable?

Medigen Biotechnology ROCO:3176 +5.57% 58 Total Tax Payable is NT$8 Mil as of Jun. 2026. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$32.73 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Medigen Biotechnology's Total Tax Payable for the quarter that ended in Jun. 2026 was NT$8 Mil.

Medigen Biotechnology's quarterly Total Tax Payable increased from Dec. 2025 (NT$13 Mil) to Mar. 2026 (NT$16 Mil) but then declined from Mar. 2026 (NT$16 Mil) to Jun. 2026 (NT$8 Mil).

Medigen Biotechnology's annual Total Tax Payable declined from Dec. 2023 (NT$25 Mil) to Dec. 2024 (NT$13 Mil) and declined from Dec. 2024 (NT$13 Mil) to Dec. 2025 (NT$13 Mil).

Medigen Biotechnology Total Tax Payable Related Terms

Medigen Biotechnology Total Tax Payable Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Total Tax Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Total Tax Payable Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Tax Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 22.99 24.63 12.73 12.66

Medigen Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Tax Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.53 7.79 12.66 15.83 8.15
ROCO:3176
58GF Score
Medigen Biotechnology Corp ROCO:3176
Total Tax Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Total Tax Payable Calculation

Total Tax Payable is the taxes liability owed to federal, state, and local tax authorities. It is the carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.

Frequently Asked Questions Learn more about Total Tax Payable →
What does a Total Tax Payable of NT$8 Mil mean?
Medigen Biotechnology (ROCO:3176) has a Total Tax Payable of NT$8 Mil as of Jun. 2026. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Total Tax Payable too high?
Medigen Biotechnology's current Total Tax Payable is NT$8 Mil. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Total Tax Payable compare to VRTX and REGN?
Medigen Biotechnology's Total Tax Payable of NT$8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Tax Payable for a Biotechnology company?
A good Total Tax Payable depends on the Biotechnology industry context. However, Total Tax Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Tax Payable mean?
A high Total Tax Payable can signal that a stock is expensive relative to its fundamentals. Tax Payable is the taxes liability owed to federal, state, and local tax authorities. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Total Tax Payable is NT$8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$32.73, compared to a current price of NT$39.80 — trading 21.6% above its estimated fair value. The current Total Tax Payable is NT$8 Mil. Medigen Biotechnology's overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Tax Payable calculated?
Total Tax Payable is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Total Tax Payable is NT$8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be overvalued. The current stock price of NT$39.80 is trading 21.6% above its estimated GF Value™ of NT$32.73. GuruFocus considers Medigen Biotechnology to be Modestly Overvalued.

Key valuation signals for ROCO:3176:

  • Total Tax Payable: NT$8 Mil
  • GF Value™: NT$32.73 vs. price of NT$39.80 (21.6% above fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score

Get the complete analysis for ROCO:3176

Total Tax Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$39.80
Price
NT$32.73
GF Value